CADASIL is the most frequent hereditary cerebral small vessel disease and is typically caused by cysteine-altering variants in NOTCH3. Prior work has shown that mutation location within the epidermal growth factor–like repeat (EGFr) domains of the NOTCH3 receptor influences phenotypic expression. This study investigated whether the same pathogenic NOTCH3 variant, p.Arg1231Cys, produces consistent clinical and imaging features across different recruitment contexts, and whether additional factors, including genetic background and cardiovascular risk markers, modify disease expression.
The analysis compared individuals harbouring the NOTCH3 p.Arg1231Cys variant across three distinct European settings: a multigenerational founder population from Cilento, Italy (CILCAD); a population-based cohort from the UK Biobank (UKB); and a clinically referred cohort from the national referral centre at Lariboisiere Hospital, Paris, France (LRB).
Investigators compared clinical features, MRI markers, and cardiovascular risk factors among carriers in these cohorts. Within the CILCAD founder population, carriers were compared with non-carriers from the same community. The NOTCH3 locus in CILCAD was analysed to define the shared haplotype carrying the mutation and to explore potential genetic contributions to phenotypic variability.
Details on specific MRI metrics, sample sizes, or statistical effect estimates are reported in the full preprint; the abstract summarizes the comparative approach and key observations.
Comparing carriers of the identical NOTCH3 p.Arg1231Cys mutation across the three European cohorts revealed marked, context-dependent phenotypic variability. Across settings the variant’s expression ranged from apparently asymptomatic carriage to manifest CADASIL. Clinical features and MRI markers differed by recruitment context, indicating that the same variant does not produce a uniform phenotype across populations and ascertainment strategies.
The study highlights that factors beyond simple mutation location within the NOTCH3 receptor can influence presentation. Recruitment setting and population context were associated with substantial differences in observed disease expression for p.Arg1231Cys carriers.
In the multigenerational Cilento founder population (CILCAD), haplotype analysis identified a shared haplotype carrying the NOTCH3 mutation. That haplotype was also associated with decreased LDL cholesterol levels in this sample, producing an unusually low LDL profile among carriers in this population.
Unexpectedly, these very low LDL levels in the CILCAD sample were associated with a higher likelihood of stroke among carriers. The observation suggests a paradoxical relationship in this specific genetic and population context: exceptionally low LDL cholesterol coincided with greater disease severity (higher stroke occurrence) among individuals carrying the p.Arg1231Cys variant.
The findings indicate that for carriers of NOTCH3 p.Arg1231Cys, determinants of disease expression extend beyond mutation position. Genetic background linked to a founder haplotype in the Cilento population appears to modify cardiovascular risk factor profiles (notably LDL) and correlate with stroke risk in that setting.
These results support a model in which population-specific genetic architecture and recruitment context can substantially shape clinical and imaging expression of a single pathogenic NOTCH3 variant. The Cilento observations raise the possibility that interactions between monogenic variants and local genetic or metabolic factors (here LDL cholesterol) may influence cerebrovascular outcomes in ways that are not predictable solely from the causal NOTCH3 change.
This report is a preprint and has not been peer reviewed; the authors note that the manuscript should not be used to guide clinical practice until peer-reviewed confirmation is available. The abstract does not provide granular numerical results or detailed MRI metric values; readers should consult the full preprint for complete methods and results.
Data originate from three sources. UK Biobank data are accessible to bona fide researchers through UKB procedures. Individual-level Cilento and French referral-centre data are not publicly available owing to privacy, ethical and legal restrictions; access may be considered on reasonable request subject to institutional approvals. The authors declared no competing interests and reported ethics approvals from the relevant institutional review boards for the work described.